TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* female patients~* 21 years of age or older~* histologically/cytologically confirmed carcinoma of the breast~* documented locally recurrent or metastatic disease not amenable to curative surgery or radiotherapy~* either one, two or three prior chemotherapy regimens~* prior treatments including both an anthracycline and a taxane and patient no longer candidate for these drugs~* measurable or non-measurable disease according to RECIST 1.1~* Karnofsky performance score of at least 70 %~* adequate haematological, hepatic and renal functions~* ECG without clinically relevant abnormality~Exclusion Criteria:~* known or clinical evidence of brain metastasis or leptomeningeal involvement~* pulmonary lymphangitis or symptomatic pleural effusion~* any serious, concurrent uncontrolled medical disorder~* history of second primary malignancy~* preexisting motor/sensory peripheral neuropathy~* known history of HIV infection~* prior therapy with capecitabine and/or vinca-alkaloids~* history of severe hypersensitivity to vinca alkaloids and/or to fluoropyrimidine or contra indication to any of these drugs~* known or suspected dihydropyrimidine dehydrogenase (DPD) deficiency~* pregnancy or breast feeding

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vinflunine plus Capecitabine (Type: EXPERIMENTAL): Patients received (in combination with capecitabine)~• Vinflunine at the dose of 280 mg/m² and as a 20-minute IV. infusion on day 1 of each cycle repeated every 3 weeks.
- Capecitabine single-agent (Type: ACTIVE_COMPARATOR): Capecitabine at the dose of 825mg/m² per os twice per day each morning and each evening for 14 consecutive days beginning on day 1 of each cycle repeated every 3 weeks (self-administered).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Therapy to Treat Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18 - 79 years~* Documented OSA (AHI \> 10 events/hr Non rapid eye movement sleep supine)~* If treated then, current CPAP use (\>4 hrs CPAP/night for \> 2 months)~Exclusion Criteria:~* Any uncontrolled medical condition~* Any other sleep disorder (Periodic leg movement syndrome, restless legs syndrome, insomnia, etc.)~* Use of medications known to affect sleep/arousal, breathing, or muscle physiology~* Allergy to lidocaine or Afrin~* Claustrophobia~* Alcohol consumption within 24 hours of PSG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive both a sugar pill and room air during their overnight sleep studies
- Treatment (Type: ACTIVE_COMPARATOR): Subjects will receive both Lunesta (eszopiclone) and medical grade oxygen during their overnight sleep studies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Age ≥1 year~* Weight \>10 Kg~* P. falciparum mono-infection, density of at least 20 parasites/μL~* Axillary temperature \< 37.5ºC~* Resident in the study area and willingness to reside for the duration of the study~* Written informed consent (plus an assent in children \>12years of age)~Exclusion Criteria:~* G6PD Deficiency Haemoglobin \<8g/dl~  * Known allergy to any of the study medications~ * Known Pregnancy or breastfeeding~ * Clear/documented history of anti-malarial treatment 2 weeks before contact with study team~ * History of blood transfusion in the previous 3 months~ * Any chronic or acute conditions that might interfere with the study as judged by the research clinician~ * History of sickle cell anaemia

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Eurartesim (control) (Type: OTHER): All participants will receive a complete course of DHA-PPQ (Eurartesim)
- Primaquine 0.75mg base/kg (Type: EXPERIMENTAL): Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.75mg/kg body weight
- Primaquine 0.4mg base /kg (Type: EXPERIMENTAL): Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.4mg base/kg Body weight
- Primaquine 0.2mg base/kg (Type: EXPERIMENTAL): Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.2mg base/kg body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Microvascular Function of GLP-1 and Its Analogues

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lean BMI ≤ 25.0 kg/m2~* Obese BMI ≥30.0kg/m2~* Non diabetic subjects and subjects with Type 2 diabetes on stable medication for at least 3 months~Exclusion Criteria:~* cardiovascular disease~* Raynaud's disease~* current treatment with any anti-hypertensive~* lipid lowering therapies~* severe hepatic impairment~* pregnancy and lactation~* subjects with Type 2 diabetes on insulin therapy~* subjects with Type 2 diabetes on sulphonylureas~* subjects with Type 2 diabetes on incretin based therapies~* subjects with Type 2 diabetes and peripheral vascular disease~* subjects with Type 2 diabetes and history of advanced retinopathy~* subjects with Type 2 diabetes and advanced nephropathy~* subjects with Type 2 diabetes with uncontrolled diabetes (HbA1c \> 8.5%)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- DPP-IV inhibitor (Type: ACTIVE_COMPARATOR): Linagliptin 5mg (Tradjenta) before microinjection of GLP-1 and its analogues
- Placebo pill (Type: PLACEBO_COMPARATOR): One placebo tablet before microinjection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HR+ post-menopausal patients with non-metastatic breast cancer~Exclusion Criteria:~* Any of the following: HR-, non-menopausal patient, metastatic breast cancer

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 37 weeks gestation~* exposure to opiates in utero~* demonstration of signs and symptoms of neonatal abstinence syndrome requiring treatment~Exclusion Criteria:~* major congenital malformations and/or intrauterine growth retardation~* medical illness requiring intensification of medical therapy~* concomitant benzodiazepine or severe alcohol abuse, self-report of regular use of alcohol or of benzodiazepines use in the past 30 days, and/or receipt of benzodiazepines by prescription (as determined by self-report or intake urine) by the mother during pregnancy,~* concomitant use of CYP 3A inhibitors (erythromycin, clarithromycin, ketoconazole, itraconazole, HIV protease inhibitors) or inducers (rifampin, carbamazepine, phenobarbital) prior to initiation of NAS treatment~* seizure activity or other neurologic abnormality~* breast feeding~* inability of mother to give informed consent due to co-morbid psychiatric diagnosis~* hypoglycemia requiring treatment with intravenous glucose

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oral morphine solution (Type: ACTIVE_COMPARATOR): Oral morphine solution
- Buprenorphine (Type: EXPERIMENTAL): Sublingual buprenorphine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically documented uterine papillary serous carcinoma (UPSC) with no visible residual disease.~2. Surgical staging to include total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal washings, and lymph node samplings.~3. Age \> 18 years.~4. ECOG performance status of \< 2.~5. Written voluntary informed consent.~Exclusion Criteria:~1. Patient has impairment of hepatic, renal or hematologic function as defined by the following baseline laboratory values:~   1. Serum SGOT and /or SGPT \> 2.5 times the institutional upper limit of normal~  2. Total serum bilirubin \> 1.5 mg/dl~  3. History of chronic or active hepatitis~  4. Serum creatinine \> 2.0 mg/dl~  5. Platelets \< 100,000/mm3~  6. Absolute neutrophil count (ANC) \< 1500/mm3~  7. Hemoglobin \< 8.0 g/dl (the patient may be transfused prior to study entry)~2. Patient has severe or uncontrolled concurrent medical disease (eg. uncontrolled diabetes, unstable angina, myocardial infarction within 6 months, congestive heart failure, etc.)~3. Patient has been treated with myelosuppressive chemotherapy within three weeks prior to study entry.~4. Patient with any prior chemotherapy or radiotherapy for pelvic malignancy.~5. Patients with dementia or altered mental status that would prohibit the giving and understanding of informed consent at the time of study entry.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Drug:Carboplatin and Paclitaxel and Radiation: Pelvic Radiation Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DNA Vaccine for Ragweed Allergic Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult men and women 18 to 60 years of age;~* Who provide informed consent;~* Have a history of fall, seasonal, allergic rhinitis consistent with ragweed allergy;~* Exhibit a positive skin test to licensed , standardized, ragweed extract and a positive acute response to ragweed nasal challenge;~* Are in general good health; and are available for the duration of the study.~Exclusion Criteria:~* Individuals with medical conditions or taking medications that might interfere with interpretation of the study results will be excluded.~* Those with a history of severe symptoms of allergic rhinitis during the spring and summer grass pollen season will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria.~1. Age more than 18 years~2. Both sexes~3. all races/ethnic groups.~4. Meeting the clinical diagnosis of Parkinson's disease with presence of moderate to severe Parkinson tremor that is refractory to standard medical treatments and which limits the patients functionality and/or poses significant discomfort.~5. Subjects who are able to read, speak, and understand English.~Exclusion Criteria.~1. Existing significant acute medical condition (i.e. cardiovascular, endocrine, hematologic, neoplastic, infectious, or autoimmune disorders) or significant swallowing or breathing difficulties.~2. Pregnancy or planned pregnancy (determined by urine pregnancy test).~3. Active breast feeding.~4. Enrollment in any clinical trial (currently or within the past 3 months) in which treatments are imposed by a protocol.~5. Any subject for whom botulinum toxin treatment would be contraindicated; known allergy or sensitivity to medication.~6. Subjects who are younger than 18 years of age. Neuromuscular-junction disorders.~7. Evidence of acute pathology in neuro-imaging.~8. Axis I diagnosis determined by a neurologist or psychiatrist.~9. Use of Anesthetic medications within two weeks and corticosteroid injections within 4 weeks of enrollment.~10. Those who received botulinum toxin injections in the past 4 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo, then Xeomin (Type: ACTIVE_COMPARATOR): Subjects randomized to receive the placebo ( saline) will receive an equivalent volume as the active study drug (1cc). The injections will be into -10 hand and forearm muscles. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. The subject will then cross over to an Active Intervention arm to receive incobotulinumtoxinA which will be injected in the same pattern as the saline.
- Xeomin, then Placebo (Type: ACTIVE_COMPARATOR): Subjects will all receive injections with incobotulinumtoxinA injections, 100unit/cc into 6-10 muscles of the forearm. A series of rating scale and an examination will take place prior to treatment and at 4 and 8 weeks post treatment. These subjects will then cross over and receive placebo ( saline) in the same distribution as their second treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have ADHD.~* Must be 13-16 years of age.~* Must be able to swallow capsules.~* Expected to achieve score of 70 or more on IQ test~* Willing and reliable to keep appts. for clinic visits and test~Exclusion Criteria:~* Treatment within last 30 days with a drug that has not received regulatory approval for any indication.~* Patients who weigh less than 40 kg or greater than 70 kg.~* Patients with documented history of Bipolar I or II disorder, or psychosis~* Patients with documented history of autism, asperger's syndrome or pervasive developmental disorder

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of URC102 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male volunteers~Exclusion Criteria:~* Received other investigational drug within 12 weeks prior to the first dose of study drug

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- URC102 (Type: ACTIVE_COMPARATOR): URC102

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 1years to less than 5 years for the younger children group; 5- less than18 years for older children and adolescent group and 18- 45 years (inclusive) for the adult group.~2. Sex: Male, Female, Transgender.~3. Consent: Informed consent from study participants and guardian in case of children along with assent in children 11-17 years (inclusive) of age.~4. Apparently healthy.~Exclusion Criteria:~1. Suffering from diarrhoea or abdominal pain or vomiting in the past 24 hours or diarrhoea lasting for more than 2 weeks in the past 6 months~2. History of taking oral cholera vaccine.~3. History of taking any other live or killed enteric vaccine in the last 8 weeks.~4. History of anaphylaxis or serious vaccine reaction.~5. Currently use of any immunosuppressive or immune-modifying drugs.~6. Receipt of blood or blood products or parenteral immunoglobulin preparation in the past 3 months.~7. Currently on antimicrobial therapy (taking antibiotics within 24 hours during screening and vaccination).~8. Severe malnutrition defined as wt-for-ht z-score \<-3.0 with or without oedema.~9. For married females pregnancy or plans to become pregnant during the study period (as determined by verbal screening) will be excluded. In addition, pregnancy test will be done by pregnancy strip test before each day of vaccination (Day 0 and day 14) for married female.~10. Culture positive V. cholerae, ETEC, Salmonella and Shigella in stool.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- HL-OCV (Type: EXPERIMENTAL): Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
- Shanchol (Type: ACTIVE_COMPARATOR): The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Histologically documented diagnosis of GIST~* Resectable GIST~* GIST removed at open surgery~* Immunohistochemical documentation of GIST (immunostaining for KIT/CD117)~* High risk of tumor recurrence as defined as one of the following: 1) the largest tumor diameter greater than 10.0 cm (measured by a pathologist, with any mitotic count); 2) mitotic count over 10 mitoses per 50 high power fields (HPFs) (with any tumor size); the largest tumor diameter larger than 5.0 cm and the mitotic count is over 5/50 HPFs; 4) tumor spillage into the abdominal cavity at surgery (or tumor rupture). No residual tumors must be present at laparotomy, or in postoperative CT or MRI examinations. Patients who have microscopically infiltrated margins (or suspected microscopical infiltration, R1) are also allowed to enter study.~* Performance status 0, 1, or 2 (ECOG)~* Adequate organ function, defined as follows: total bilirubin \<1.5 x ULN (upper limit of normal), serum AST (SGOT) and ALT (SGPT) \<2.5 x ULN, creatinine \<1.5 x ULN, ANC (neutrophil count) \>1.5 x 10\^9/L, platelets \>100 x 10\^9/L.~* Negative pregnancy test (females with childbearing potential)~* Written, voluntary informed consent~Exclusion Criteria:~* Inoperable or metastatic GIST~* Less than 1 week or more than 12 weeks has elapsed from surgery~* Recurrent GIST~* Patient has received any investigational agents within 28 days as calculated from the first day of the study drug dosing~* Patient is less than 5 years free from another primary malignancy~* Patient with grade III/IV cardiac problems as defined by the New York Heart Association Criteria~* Female patients who are pregnant or breast-feeding~* Patient has severe or uncontrolled medical disease (i.e. uncontrolled diabetes, severe chronic renal disease, or active uncontrolled infection). Concurrent use of warfarin or acetaminophen are not allowed with imatinib.~* Chronic liver disease~* Known diagnosis of human immunodeficiency virus (HIV) infection~* Patient has received chemotherapy for GIST~* Patient has received neoadjuvant imatinib therapy prior to randomization~* Radiotherapy to 25% or more of the bone marrow~* Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 1 year of adjuvant imatinib mesylate 400 mg/day orally
- 2 (Type: EXPERIMENTAL): 3 years of adjuvant imatinib mesylate 400 mg/day orally

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete